文献速递淋巴瘤血栓与止血造血干细胞移植与细胞治疗

CD19 CAR-T治疗B淋巴母细胞淋巴瘤并发弥散性血管内凝血一例报告及文献复习

[CD19 CAR-T treatment for B-lymphoblastic lymphoma complicated with disseminated intravascular coagulation: a case report and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

回顾性分析1例32岁男性B淋巴母细胞淋巴瘤患者在接受CAR-T细胞(4×10^6/kg)治疗后出现2级细胞因子释放综合征、鼻出血及弥散性血管内凝血伴持续性低纤维蛋白原血症的临床经过,经托珠单抗、糖皮质激素及血制品和纤维蛋白原替代治疗后好转,并检索中英文数据库复习相关文献。

要点

  • CAR-T相关出凝血障碍伴随细胞因子释放综合征发生,低纤维蛋白原血症为其特征。
  • 进展至弥散性血管内凝血时可危及生命。
  • 拮抗细胞因子释放综合征和替代治疗为有效治疗手段。

核心结论

  • CAR-T细胞治疗相关出凝血障碍伴随细胞因子释放综合征发生,低纤维蛋白原血症是其特征,进展至弥散性血管内凝血时危及生命,拮抗细胞因子释放综合征和替代治疗是有效治疗手段。

研究设计与样本

  • 回顾性收集2020年4月于华中科技大学同济医学院附属协和医院血液科接受CAR-T细胞治疗的1例B淋巴母细胞淋巴瘤患者的临床资料并进行分析。
  • 以「嵌合抗原受体T细胞治疗」「凝血」「出血」「血栓」「CAR-T」「coagulation」「bleeding」「thrombosis」为检索词,检索建库至2024年11月中国知网数据库、万方数据库及PubMed数据库进行文献复习,共检索到相关英文文献20篇、中文文献6篇。

主要发现

  • 患者为32岁男性,确诊B淋巴母细胞淋巴瘤10个月余,在3个周期化疗及异基因造血干细胞移植后复发,骨髓细胞学提示20.24%为表型异常的B系原始细胞。
  • 回输CAR-T细胞4×10^6/kg后第2天出现2级细胞因子释放综合征,第4天发生鼻出血,第9天再发高热,凝血指标恶化,并发弥散性血管内凝血、持续性低纤维蛋白原血症。
  • 予以托珠单抗、糖皮质激素拮抗细胞因子释放综合征,输注血制品及补充纤维蛋白原积极替代治疗后,患者细胞因子释放综合征及凝血异常逐渐恢复。
  • CAR-T细胞治疗后规律随访16个月,体内CAR-T细胞持续存在,骨髓流式细胞术微小残留病维持阴性;后因患者自行停用口服抗排异药物,排异加重合并感染,患者及家属要求出院而失访。

局限性

  • 本文为单例病例报告及文献复习,患者后因自行停用口服抗排异药物致排异加重合并感染,要求出院而失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the clinical manifestations, pathogenesis, and therapeutic approaches of disseminated intravascular coagulation (DIC) associated with chimeric antigen receptor T-cell (CAR-T) therapy for B-lymphoblastic lymphoma. Methods: Retrospective collection and analysis were conducted on the clinical data of a patient with B-lymphoblastic lymphoma who received CAR-T therapy in the Hematology Department of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, in April 2020. To review the literatures, Chinese databases (CNKI, Wanfang Database) and PubMed were searched form database inception up to November 2024 using the retrieval entries "chimeric antigen receptor T-cell therapy", "CAR-T", "coagulation", "bleeding", and "thrombosis" . Results: The patient, a 32-year-old male, diagnosed with B-lymphoblastic lymphoma for over 10 months, relapsed after three cycles of chemotherapy and allogeneic hematopoietic stem cell transplantation, with bone marrow cytology indicating 20.24% abnormal phenotype B-lineage precursor cells. After CAR-T cell infusion at a dose of 4×10(6)/kg, the patient developed grade 2 cytokine release syndrome (CRS) on day 2, nasal bleeding on day 4, high fever again on day 9, with worsening coagulation parameters, DIC and persistent hypofibrinogenemia. After treatment with tocilizumab, corticosteroids to counteract CRS, and active replacement therapy such as administration of blood product and fibrinogen, the patient's CRS and coagulation abnormalities gradually improved. The patient was followed up for 16 months regularly after CAR-T therapy, with CAR-T cells sustained and minimal residual disease remained negative as assessed by bone marrow flow cytometry. Subsequently, the patient stopped taking oral immunosuppressants on his own, which aggravated rejection reaction complicated with infection. The patient and his family requested to be discharged and lost the follow-up. A total of 20 relevant English articles and 6 Chinese articles were retrieved from the literature search. Conclusion: CAR-T-associated coagulopathy occurs alongside CRS. It is characterized by hypofibrinogenemia, and is life-threatening when progressing to DIC. Anti-CRS and replacement therapies have proven to be effective treatment strategies. 目的: 探讨嵌合抗原受体T细胞(CAR-T细胞)治疗B淋巴母细胞淋巴瘤后并发DIC的临床表现、发生机制和诊疗方案。 方法: 回顾性收集2020年4月于华中科技大学同济医学院附属协和医院血液科接受CAR-T细胞治疗的1例B淋巴母细胞淋巴瘤患者的临床资料并进行分析。以"嵌合抗原受体T细胞治疗""凝血""出血""血栓""CAR-T""coagulation""bleeding""thrombosis"为检索词,检索建库至2024年11月中文数据库(中国知网数据库、万方数据库)及Pubmed数据库进行文献复习。 结果: 患者为32岁男性,确诊B淋巴母细胞淋巴瘤10个月余,在3个周期化疗及异基因造血干细胞移植后复发,骨髓细胞学提示20.24%为表型异常的B系原始细胞。回输CAR-T细胞4×10(6)/kg后第2天,患者出现2级细胞因子释放综合征(CRS),第4天发生鼻出血,第9天再发高热,凝血指标恶化,并发DIC、持续性低纤维蛋白原血症。予以托珠单抗、糖皮质激素拮抗CRS,输注血制品及补充纤维蛋白原积极替代治疗后,患者CRS及凝血异常逐渐恢复。CAR-T细胞治疗后规律随访16个月,体内CAR-T细胞持续存在,骨髓流式细胞术MRD维持阴性。后因患者自行停用口服抗排异药物,排异加重合并感染,患者及家属要求出院而失访。文献检索共检索到相关英文文献20篇,中文文献6篇。 结论: CAR-T细胞治疗相关出凝血障碍伴随CRS发生,低纤维蛋白原血症是其特征,进展至DIC时危及生命,拮抗CRS和替代治疗是有效治疗手段。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li YY, Li PR, Jiang HW, et al. [CD19 CAR-T treatment for B-lymphoblastic lymphoma complicated with disseminated intravascular coagulation: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 40032330. doi:10.3760/cma.j.cn121090-20241202-00523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。